Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1324
Name lung cancer
Definition A respiratory system cancer that is located_in the lung.
Source DiseaseOntology.org
Alt Ids DOID:13075 DOID:9881 DOID:1322
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047R Dactolisib lung cancer sensitive detail...
PIK3CA H1047R Sirolimus lung cancer no benefit detail...
EML4 - ALK ALK G1202R Lorlatinib lung cancer conflicting detail...
FGFR1 amp Brivanib lung cancer no benefit detail...
ATR positive Berzosertib + Cisplatin lung cancer sensitive detail...
FGFR1 amp AZD4547 lung cancer sensitive detail...
FGFR1 wild-type AZD4547 lung cancer decreased response detail...
TP53 wild-type KRT-232 lung cancer sensitive detail...
TP53 loss KRT-232 lung cancer resistant detail...
TP53 wild-type KRT-232 + Radiotherapy lung cancer sensitive detail...
TP53 loss KRT-232 + Radiotherapy lung cancer resistant detail...
CDKN2A del PF-00477736 + PF3644022 lung cancer predicted - sensitive detail...
EML4 - ALK X-376 lung cancer sensitive detail...
FGFR1 amp Erdafitinib lung cancer predicted - sensitive detail...
FGFR1 amp GSK3052230 lung cancer sensitive detail...
BRAF V600E Ulixertinib lung cancer sensitive detail...
BRAF L597Q Ulixertinib lung cancer sensitive detail...
CTNNB1 T41A NTRC 0066-0 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps-BAY2b lung cancer predicted - sensitive detail...
CTNNB1 T41A NMS-P715 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1161909 lung cancer predicted - sensitive detail...
CTNNB1 T41A BAY1217389 lung cancer predicted - sensitive detail...
CTNNB1 T41A Mps1-IN-1 lung cancer predicted - sensitive detail...
CTNNB1 T41A MPI-0479605 lung cancer predicted - sensitive detail...
NRAS Q61K RAF709 lung cancer sensitive detail...
ATM positive AZD1390 lung cancer sensitive detail...
FGFR1 amp PD173074 lung cancer sensitive detail...
BRAF G469A RMC-4550 lung cancer resistant detail...
BRAF G466V RMC-4550 lung cancer predicted - sensitive detail...
EML4 - ALK ALK L1152R Ceritinib lung cancer resistant detail...
MAP2K1 E41_L54del Trametinib lung cancer sensitive detail...
MAP2K1 E41_L54del Cobimetinib lung cancer sensitive detail...
MAP2K1 E41_L54del Selumetinib lung cancer sensitive detail...
MAP2K1 E41_L54del LY3009120 lung cancer no benefit detail...
FGFR1 amp FGFR1 over exp Rogaratinib lung cancer sensitive detail...
FGFR1 amp FGFR1 over exp Docetaxel + Rogaratinib lung cancer sensitive detail...
FGFR1 amp FGFR1 over exp Carboplatin + Paclitaxel + Rogaratinib lung cancer sensitive detail...
FGFR1 over exp Rogaratinib lung cancer predicted - sensitive detail...
FGFR1 over exp Docetaxel + Rogaratinib lung cancer predicted - sensitive detail...
BRAF G466V PLX8394 lung cancer predicted - sensitive detail...
EML4 - ALK Bevacizumab + Lorlatinib lung cancer predicted - sensitive detail...
MAP2K1 Q56P LY3214996 lung cancer predicted - sensitive detail...
FGFR2 fusion RLY-4008 lung cancer predicted - sensitive detail...
FGFR1 amp Futibatinib lung cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed USA 3
NCT01470209 Phase I Buparlisib + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed USA 0
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Active, not recruiting USA 0
NCT01935336 Phase II Ponatinib Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Active, not recruiting USA 0
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated USA 0
NCT02155465 Phase Ib/II Erlotinib + Ruxolitinib Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Completed USA 0
NCT02241369 Phase I INO-3106 + INO-9012 Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies Completed USA 0
NCT02264236 Phase Ib/II Montanide ISA 51 + P10s-PADRE Vaccination of Advanced-Stage Lung Cancer Patients Withdrawn USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02429843 Phase I Carboplatin + Paclitaxel Bevacizumab Carotuximab A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Completed USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated USA 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting USA | CAN 29
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Recruiting USA 0
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Active, not recruiting USA | CAN 5
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03373760 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Active, not recruiting USA 0
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Recruiting USA 0
NCT03597009 Phase Ib/II Nivolumab + Talimogene laherparepvec A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Terminated USA 0
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Not yet recruiting 1
NCT04085315 Phase I Alisertib + Osimertinib Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Recruiting USA 0
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Active, not recruiting USA 2
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Recruiting 1
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting USA 2
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04287868 Phase Ib/II M7824 + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Suspended USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Recruiting USA | CAN 0
NCT05060432 Phase Ib/II EOS-448 + Pembrolizumab EOS-448 + EOS100850 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) Recruiting USA 1